In a recent report by Bischoff et al.,1 the authors reported the predictive and prognostic significance of KRAS and TP53 mutations in determining the efficacy of first-line pembrolizumab treatment among a cohort of German patients with nonsquamous PD-L1-high (≥50%) NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.